Coldstream Capital Management Inc. Buys New Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Coldstream Capital Management Inc. purchased a new position in ICU Medical, Inc. (NASDAQ:ICUI) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,250 shares of the medical instruments supplier’s stock, valued at approximately $227,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in shares of ICU Medical by 9.6% in the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after purchasing an additional 48,106 shares during the last quarter. Barclays PLC grew its holdings in ICU Medical by 15.6% in the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after acquiring an additional 8,010 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of ICU Medical in the third quarter valued at about $342,000. EP Wealth Advisors LLC bought a new position in shares of ICU Medical during the third quarter valued at about $247,000. Finally, Jane Street Group LLC boosted its holdings in shares of ICU Medical by 137.5% during the third quarter. Jane Street Group LLC now owns 28,729 shares of the medical instruments supplier’s stock worth $5,235,000 after purchasing an additional 16,635 shares during the period. Institutional investors own 96.10% of the company’s stock.

ICU Medical Trading Down 1.6 %

NASDAQ ICUI opened at $159.06 on Tuesday. The firm has a market capitalization of $3.89 billion, a PE ratio of -34.81 and a beta of 0.62. The stock’s 50 day moving average is $170.76 and its 200 day moving average is $152.04. ICU Medical, Inc. has a twelve month low of $86.80 and a twelve month high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75.

Insider Buying and Selling at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,973,261.12. This trade represents a 10.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Christian B. Voigtlander sold 1,430 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $158.00, for a total transaction of $225,940.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,364 shares of company stock valued at $6,869,878. 6.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ICUI has been the topic of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. KeyCorp lifted their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a research report on Wednesday, December 11th. Finally, Raymond James raised their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $199.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.